Please login to the form below

Not currently logged in
Email:
Password:

HAE

This page shows the latest HAE news and features for those working in and with pharma, biotech and healthcare.

Shire bags US approval for constipation drug Motegrity

Shire bags US approval for constipation drug Motegrity

Shire isn’t viewed as having a particularly strong late-stage pipeline, but it recently picked up additional approvals for Vonvendi/Veyvondi for von Willebrand disease and its hereditary angioedema (HAE) ... therapy Cinryze, and has also just had a

Latest news

  • Shire’s angioedema drug Takhzyro claims EU approval Shire’s angioedema drug Takhzyro claims EU approval

    The company maintains that Takhzyro has the potential to expand the HAE prevention market, particularly in international markets, as it is easier to administer than other drugs. ... Analysts at Bernstein recently predicted that Takhzyro will eventually

  • Shire’s angioedema drug Takhzyro recommended in Europe Shire’s angioedema drug Takhzyro recommended in Europe

    Takhzyro has been recommended for prevention of recurrent attacks of hereditary angioedema (HAE) a rare, genetic disorder that results in recurring attacks of oedema in parts of the body, including the ... The drug isn’t the first HAE treatment on the

  • Shire claims US okay for HAE blockbuster-in-waiting Shire claims US okay for HAE blockbuster-in-waiting

    community. “HAE attacks are painful, debilitating, and potentially life threatening,” commented Anthony Castaldo, president of the US Hereditary Angioedema Association. ... Takhzyro provides the HAE community with a new option for the prevention of

  • Immunology keeps Shire figures solid as Takeda takeover nears Immunology keeps Shire figures solid as Takeda takeover nears

    Shire recently picked up additional approvals for Vonvendi/Veyvondi for von Willebrand disease and its hereditary angioedema (HAE) therapy Cinryze and has three new therapies filed for approval, namely lanadelumab for ... HAE, prucalopride (SHP555) for

  • EMA starts rapid review of Shire’s HAE antibody EMA starts rapid review of Shire’s HAE antibody

    two weeks resulted in an 87% reduction in the mean frequency of HAE attacks overall, according to Shire. ... Other approved treatments for HAE include CSL Behring’s Berinert and Pharming’s Ruconest.

More from news
Approximately 5 fully matching, plus 22 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    The first test of this will be Shire’s new blockbuster-in-waiting Takhzyro, which gained EMA approval in November, for the rare disease hereditary angioedema (HAE). ... Analysts at Bernstein recently predicted that Takhzyro will eventually dominate the

  • A rare talent A rare talent

    and HAE.”.

  • Deal Watch November 2015 Deal Watch November 2015

    Given that Shire's Cinryze is already approved in HAE, It will be interesting to see what the regulators say on the anti-competition front. ... 160, 000. Dyax Corporation. Shire. Acquisition - company. Includes KALBITOR marketed for acute attacks of HAE

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics